Lacer Patent-Cliff Exposure & CMS Drug Spending Portfolio

Lacer (US): 2 reconciled FDA prescription therapies, $15.2M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2033-01-01
2024 CMS Total Public Spend$15.2M
2024 Medicare Part D Spend$4.9M
2024 Medicaid Spend$10.3M
California HCAI SB 17 Filings1 WAC filings (max 31.6% 2-yr change)